Diphenhydramine Shortage: What Providers and Prescribers Need to Know in 2026

Drug shortages continue to affect clinical workflows across specialties. Diphenhydramine — one of the most commonly used first-generation antihistamines — has had its own supply challenges in recent years. This briefing covers what providers need to know about the current status, clinical implications, and how to help patients navigate access.

Shortage Timeline and Current Status

The most significant Diphenhydramine shortage in recent years involved the injectable formulation (50 mg/mL). Here's the timeline:

• March 2022: ASHP reported an active shortage of Diphenhydramine injection. Multiple manufacturers faced production issues.
• 2022-2024: Supply remained intermittent. Hospitals and infusion centers were most impacted, particularly for premedication protocols before chemotherapy and blood product transfusions.
• May 2025: Sagent Pharmaceuticals confirmed all marketed injectable presentations were available. The shortage was effectively resolved.
• 2026: Both oral and injectable formulations are in stable supply. No active FDA shortage listing for any Diphenhydramine product.

Oral OTC formulations (tablets, capsules, liquids) were not formally part of the shortage, though localized stock-outs have occurred during peak allergy and cold/flu seasons.

Prescribing Implications

While the formal shortage is resolved, providers should keep several prescribing considerations in mind:

Elderly Patients

Diphenhydramine is on the American Geriatrics Society Beers Criteria as a potentially inappropriate medication for adults 65 and older. The anticholinergic burden increases the risk of confusion, falls, urinary retention, and cognitive decline. For this population, second-generation antihistamines are preferred.

Drug Interactions

Diphenhydramine inhibits CYP2D6, which can affect plasma levels of drugs metabolized by this pathway (e.g., Metoprolol, Codeine, Tamoxifen). It also has additive effects with other anticholinergic agents, CNS depressants, and alcohol. MAO inhibitors are contraindicated due to intensified anticholinergic effects.

OTC Self-Medication Risks

Many patients use Diphenhydramine without discussing it with their provider. It appears in numerous OTC products (cold medicines, sleep aids, allergy pills) under various brand names — patients may inadvertently double-dose. Proactive screening for OTC antihistamine use is advisable during medication reconciliation.

Current Availability Picture

As of early 2026, the availability picture for Diphenhydramine is favorable:

• Oral OTC forms: Widely available. Multiple manufacturers produce generic Diphenhydramine HCl in tablets (25 mg, 50 mg), capsules, liquid, chewables, and dissolving tablets.
• Injectable (50 mg/mL): Available from Sagent and other manufacturers. The multi-year shortage has been resolved.
• Topical forms: Creams, gels, sprays, and sticks (1-2%) remain readily available OTC.

Cost and Access Considerations

Diphenhydramine is among the most affordable medications available. Generic 25 mg tablets cost $3-$9 for a 30-count supply at retail, with discount cards bringing prices as low as $2.82. Brand-name Benadryl runs $8-$15.

Because it is primarily OTC, insurance typically does not cover it. However, it is HSA/FSA eligible. For patients on tight budgets, the generic is very affordable, and no manufacturer assistance programs are needed given the low cost.

Tools and Resources for Your Practice

When patients report difficulty finding Diphenhydramine, Medfinder for Providers can help. The platform allows you and your staff to check real-time pharmacy stock for Diphenhydramine and other medications, directing patients to pharmacies that have their medication available.

Additional resources:

• FDA Drug Shortage Database — Monitor active and resolved shortages at fda.gov
• ASHP Drug Shortages Resource Center — Detailed shortage information with clinical alternatives and estimated resupply dates
• Beers Criteria (AGS) — Reference for appropriate antihistamine use in geriatric patients

Looking Ahead

The Diphenhydramine supply chain appears stable going into the remainder of 2026. The injectable shortage that impacted hospital and infusion center workflows is resolved. Oral OTC formulations face no supply constraints at the national level.

However, ongoing challenges in the broader pharmaceutical supply chain — raw material sourcing, manufacturing capacity, and distribution logistics — mean that localized or temporary disruptions can occur with any generic product. Maintaining awareness of alternative agents and access tools remains good clinical practice.

Therapeutic Alternatives at a Glance

When clinical circumstances warrant substitution:

• For allergic conditions: Cetirizine 10 mg daily, Loratadine 10 mg daily, or Fexofenadine 180 mg daily (all OTC, second-generation, preferred per AAAAI guidelines)
• For pruritus/urticaria: Hydroxyzine 25-50 mg (Rx), Cetirizine 10-20 mg
• For premedication (infusion reactions): Cetirizine oral (preferred for less sedation) or IV Diphenhydramine when available
• For insomnia: Hydroxyzine (Rx), low-dose Doxepin (Rx), or Melatonin — avoid long-term Diphenhydramine for sleep per AGS guidelines

Final Thoughts

Diphenhydramine supply has stabilized in 2026. The primary clinical consideration is not shortage but appropriate use — particularly in elderly and polypharmacy patients. When patients have difficulty locating it, Medfinder for Providers offers a practical tool for real-time stock verification.

Disclaimer: This article is for informational purposes only. Clinical decisions should be based on individual patient assessment and current guidelines.